SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 87,200
+5,000 (6.08%)
Last updated: Jun 24, 2026, 2:31 PM KST
SK Biopharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, SK Biopharmaceuticals stock has a consensus rating of "Buy" and an average price target of ₩134,818. The average 1-year stock price forecast is 54.61% higher than the current stock price, while the lowest is ₩73,000 (-16.28%) and the highest is ₩160,000 (+83.49%).
Price Target: ₩134,818 (+54.61%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SK Biopharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 7 | 7 | 5 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 14 | 14 | 13 | 12 | 10 |
Financial Forecast
Revenue This Year
963.38B
from 706.74B
Increased by 36.31%
Revenue Next Year
1.12T
from 963.38B
Increased by 16.12%
EPS This Year
3.91K
from 3.41K
Increased by 14.58%
EPS Next Year
4.91K
from 3.91K
Increased by 25.64%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 980.9B | ||
| Avg | 963.4B | ||
| Low | 940.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 38.8% | ||
| Avg | 36.3% | ||
| Low | 33.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4,756.00 | ||
| Avg | 3,906.12 | ||
| Low | 3,288.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 39.5% | ||
| Avg | 14.6% | ||
| Low | -3.5% |